When the PI3K/Akt/mTOR pathway was inhibited, a more prominent decrease in cardiac hypertrophy, NF-κB, and IκBb was noted, providing evidence that TLR4 downstream metabolites can be affected by different TLR pathways which could be contributing to cardiac hypertrophy. This evidence concerns the gene AKT1 and cardiac hypertrophy.